Company profile

BlossomHill Therapeutics

BLSM (EDGAR registrant "BlossomHill Therapeutics, Inc." listed BLSM [resolved 2026-08-05 by resolve-null-is-public; source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001839970])

Share price · BLSM

$16.10+0.10 (+0.63%) 3M

close as of 2026-08-18 · 24h delayed · vol 308K

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 1
CLK (CDC-like kinase family)
Acute Myeloid Leukemia

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.